
Partner/Owner, EYE ASSOCIATES OF WINTER PARK
Member of the Healthcare Council
Gary Barker, OD, FAAO, is a Partner and Co-Founder of the group practice Eye Associates of Winter Park, Florida. Dr. Barker is the Past-President of the Florida Optometric Association, where he remains active in legislative affairs. Clinically, he has participated in numerous Phase III FDA studies of new contact lenses and contact lens solutions. Dr. Barker is very familiar with all types of contact lenses and contact lens care systems, and stays aware of trends in the contact lens market. Dr. Barker diagnoses and treats eye disease, including glaucoma. (This is me - Update Profile)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Welcome addition to our armament, but overuse potential?
July 14, 2009
Bausch and Lomb (BOL) Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye') | www.lifescience-online.com
Potential for overuse and more drug-resistant bacteria
Will J&J's new one-day lens effect the one-day market?
November 17, 2008
Johnson & Johnson Vision Care Announces First Daily Disposable Silicone Hydrogel at BCLA | www.cltoday.com
New innovations in the contact lens market are needed to boost growth in sales, especially in the one-day lens market.
Is LASIK the issue or is choosing the right refractive surgery for the right patient the real issue?
May 7, 2008
LASIK Worries? Some May See Better with Alternatives | www.washingtonpost.com
I welcome the FDA investigation of LASIK, as thousands of patients are undergoing the elective cosmetic procedure, with some achieving less than optimum results. Will the study show that LASIK is not safe, or will it show that LASIK is not the real issue, rather that patient selection is the true issue?
Injectable glaucoma drug vs. patient compliance
April 15, 2008
Injectable glaucoma drug shown to reduce IOP in clinical study | www.osnsupersite.com
Any new efficacious glaucoma treatment is welcome and needed, but patient compliance remains a factor. A single injection treatment that provides IOP reduction for 3 months would greatly improve success in IOP control. I would, however, like to see a lower target pressure set for the study.
April 15, 2008
Novartis to buy Nestle's Alcon stakes for $39 billion | www.wtnzfox43.com
The purchase of a controlling interest in Alcon by Novartis is a brilliant move by Novartis. To bring the leading contact lens disinfectant together with Ciba's contact lenses is a wonderful marketing opportunity for Ciba.
| Study Group Name | No. Members |
|---|---|
| Experts in the Leisure & Lodging Council | 4887 |
| Experts in the Automotive Council | 3422 |
| Building Materials Industry Experts | 2005 |
| Optometrists | 370 |
| Optometrists (US) | 283 |
Gary Barker has not participated in any GLG Live Meetings.